Molecular Diagostics for Blood Banking Applications: Testing volume, cost per test, and market potential

OVERVIEW

SCOPE AND METHODOLOGY

MARKET CONTEXT

• Exhibit 1: Distribution of Molecular Diagnostics Testing in the United States, 2004

BLOOD BANKING PRACTICES, TRENDS, REGULATION

COST AND OTHER BARRIERS

PRODUCTS OF NOTE

• Exhibit 5: Commercially Available Molecular (Nucleic Acid) Tests for Blood, Plasma and Organ Donor Screening in the United States: 2004

NUMBER OF TESTS

• Exhibit 2: Projected Blood Banking and Plasmapheresis Testing by Molecular Diagnostics in the United States: 2003-2013
• Exhibit 3: Trending in the Projected Number of Blood Banking and Plasmapheresis Tests by Molecular Diagnostics in the United States: 2003-2013
• Exhibit 4: Trending in the Percentage Distribution of Blood Banking and Plasma-pheresis Tests by Molecular Diagnostics in the United States 2003-2013

MARKET AND COST PER TEST PROJECTIONS, 2003-2013

• Exhibit 5: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Market Potential in the United States: 2003-2013
• Exhibit 6: Trending in the Projected Test Volume for Molecular Diagnostics in Blood Banking Applications in the United States: 2003-2013
• Exhibit 7: Trending in the Projected Test Volume Composition for Molecular Diagnostics in Blood Banking Applications in the United States: 2003-2013
• Exhibit 8: Trending in the Projected Market Potential for Molecular Diagnostics in Blood Banking Applications in the United States: 2003-2013
• Exhibit 9: Trending in the Projected Market Potential Composition for Molecular Diagnostics in Blood Banking Applications in the United States: 2003-2013
• Exhibit 10: Trending in the Projected Average Cost Per Test for Molecular Diagnostics in Blood Banking Applications in the United States: 2003-2013

MAJOR COMPETITORS

• Abbott Diagnostics (Division of Abbott Laboratories)
• Chiron Corp.
• Gen-Probe Inc.